The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer’s disease1, 2, 3, 4. The age-specific prevalence of Alzheimer’s disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer’s disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer’s disease and cognitive decline in the elderly without Alzheimer’s disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer’s disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer’s disease, the two may be mediated through the same or similar mechanisms.
At a glance
- Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112–2117 (2005) et al.
- Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29, 125–132 (2007) et al.
- Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci. 11, 111–128 (2009) , &
- Epidemiology of Alzheimer disease. Nature reviews. Neurology 7, 137–152 (2011) , &
- Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885–890 (1984) &
- Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer’s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4, 2757–2763 (1985) et al.
- APP processing in Alzheimer’s disease. Mol. Brain 4, 3 (2011) , , &
- Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol. Cell. Neurosci. 14, 419–427 (1999) et al.
- Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402, 537–540 (1999) et al.
- β-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741 (1999) et al.
- Membrane-anchored aspartyl protease with Alzheimer’s disease β-secretase activity. Nature 402, 533–537 (1999) et al.
- APP mutations table. http://www.alzforum.org/res/com/mut/app/table1.asp (2010) &
- Alzheimer’s disease and frontotemporal dementia mutation database. http://www.molgen.ua.ac.be/ADMutations (2012)
- Molecular genetics of Alzheimer’s disease. Biol. Psychiatry 47, 183–199 (2000)
- Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families. PLoS ONE 7, e31039 (2012) et al.
- Detection of sharing by descent, long-range phasing and haplotype imputation. Nature Genet. 40, 1068–1075 (2008) et al.
- Fine-scale recombination rate differences between sexes, populations and individuals. Nature 467, 1099–1103 (2010) et al.
- A new multipoint method for genome-wide association studies by imputation of genotypes. Nature Genet. 39, 906–913 (2007) , , , &
- Identification of low-frequency variants associated with gout and serum uric acid levels. Nature Genet. 43, 1127–1130 (2011) et al.
- Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer’s disease. Neurology 43, 1254–1256 (1993) , , &
- Exome Variant Server. NHLBI Exome Sequencing Project (ESP). http://evs.gs.washington.edu/EVS/ (2012)
- A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 323, 1473–1477 (2009) et al.
- Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathol. 120, 803–812 (2010) et al.
- Mutation of the β-amyloid precursor protein in familial Alzheimer’s disease increases β-protein production. Nature 360, 672–674 (1992) et al.
- Substrate and inhibitor profile of BACE (β-secretase) and comparison with other mammalian aspartic proteases. J. Biol. Chem. 277, 4687–4693 (2002) , , , &
- Employing a superior BACE1 cleavage sequence to probe cellular APP processing. J. Neurochem. 84, 1006–1017 (2003) et al.
- MDS Cognitive Performance Scale. J. Gerontol. 49, M174–M182 (1994) et al.
- A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nature Genet. 43, 316–320 (2011) et al.
- Supplementary Information (998K)
This file contains Supplementary Text and Data, Supplementary Tables 1-2, Supplementary Figures 1-4 and Supplementary References.